| Name | Title | Contact Details |
|---|
Tarrytown Expocare Pharmacy is a specialized long-term care pharmacy dedicated to serving individuals with intellectual and developmental disabilities (IDD) and behavioral health needs. The company operates across 30 U.S. states with ten physical locations, providing institutional pharmacy services to group homes, foster families, and residential care facilities. Tarrytown Expocare focuses on efficiency and safety, offering innovative solutions like color-coded blister packs to simplify medication administration. The pharmacy provides a range of services, including medication management, clinical collaboration, compliance support, and ongoing training for caregivers and nurses. Their secure online portal allows for 24/7 access to manage prescriptions and care coordination. Tarrytown Expocare emphasizes person-centric care and regulatory compliance, aiming to improve outcomes for vulnerable populations through reliable medication delivery and collaborative pharmacy solutions.
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing agreement with Weill Cornell Medicine for the worldwide rights to develop, manufacture and commercialize XC001.
BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.
GrayBug® is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company`s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.
Tempest Therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways.